SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System
Key Highlights
- ➤37% mean IOP reduction at 48 months across all three BIM-IOL dose groups
- ➤86% of evaluable patients remained off topical IOP-lowering drops
- ➤90% of patients maintained at least 20/25 best corrected distance visual acuity
- ➤No product-related adverse events reported after four years
- ➤SpyGlass Pharma continues Phase 3 enrollment and plans 505(b)(2) NDA submission
Expert Statements
Paul Yoo, Senior Vice President of Clinical Development at SpyGlass Pharma
“Achieving four years of sustained IOP reduction, while largely eliminating the need for daily drops and maintaining a clear safety profile and excellent visual outcomes, establishes a new benchmark for durable, drop-free disease control”
Paul Yoo, Senior Vice President of Clinical Development at SpyGlass Pharma
“We look forward to gathering further long-term safety and efficacy evidence as we follow these patients through 2029.”
Patrick Mooney, Chief Executive Officer of SpyGlass Pharma
“This is the first time a sustained drug delivery implant for glaucoma therapy has demonstrated durable safety and efficacy results for four years”
Patrick Mooney, Chief Executive Officer of SpyGlass Pharma
“These remarkable results further underscore the significant potential for the BIM-IOL System to change the treatment paradigm for glaucoma patients undergoing cataract surgery.”
Patrick Mooney, Chief Executive Officer of SpyGlass Pharma
“There is a significant unmet need to address as there are approximately one million cataract procedures performed in the United States each year in patients with glaucoma.”
Patrick Mooney, Chief Executive Officer of SpyGlass Pharma
“The BIM-IOL System is designed to fit directly into every cataract surgeon’s workflow to address two of the leading causes of preventable blindness in a single procedure: restoring vision from cataracts and lowering IOP to preserve a patient’s precious sight.”
Patrick Mooney, Chief Executive Officer of SpyGlass Pharma
“We are incredibly proud of these results as they demonstrate the versatility of our drug delivery technology to provide clinically meaningful, enduring IOP control for patients.”
Groundbreaking 4-year safety and efficacy results: * 37% reduction in mean intraocular pressure (IOP) across all dose groups * 86% of patients remained off all topical IOP-lowering drops * 90% of patients maintained ≥20/25 best corrected distance visual acuity (BCDVA) * No product-related adverse events were reported IRVINE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines, today announced positive 4-year first-in-human (FIH) trial results for the Bimatoprost Drug Pad-IOL System (BIM-IOL System) in patients with mild-to-moderate open angle glaucoma (OAG) or ocular hypertension (OHT) undergoing routine cataract surgery. SpyGlass Pharma designed the FIH trial to evaluate the safety and efficacy of the BIM-IOL System in patients for seven years.
Get started
Create a free account to read the full story.